Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, insisting it will be an “important” weight loss treatment.

He and his team then compared the diagnoses for hair loss in these patients’ medical records and found that those prescribed ...

Novo Nordisk said Thursday that the rampant growth of the U.S.’ compounded drug industry was hurting Wegovy sales, and warned ...

Eli Lilly and Novo Nordisk are in a global battle for dominance in the weight loss space. BioSpace takes a look at the ...

Americans pay far more for GLP-1 drugs than citizens in other wealthy nations. If Dr. Marty Makary, the new FDA commissioner, ...

Viking Therapeutics VKTX announced that it has completed enrolling study participants in the phase II VENTURE-Oral Dosing ...

Novo Nordisk, a Danish pharmaceutical company, has signed a major deal worth up to $2 billion for the rights to a new obesity ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Novo Nordisk’s (NVO) stock has dropped by 25% in March (on the Copenhagen exchange) to put it on track for its biggest ...

Earlier this year, when US President Donald Trump offered to buy Greenland from Denmark, online rumours circulated that the Danish government might encourage Novo Nordisk, the Danish company behind ...

For weight loss to be effective, we must consider the diverse factors contributing to weight gain, which vary from person to ...